Drug Approval | February 24, 2023
SERDA therapeutics submits IND for wound debridement agent
Clinical studies are expected to start in Q2 2023.
Clinical studies are expected to start in Q2 2023.
Projected ~US$100 million cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months
The marketing authorisations for three generic drugs signifying advances in cancer treatment will considerably benefit thousands of patients by improving access, ensuring affordability
The safety profile of LAGEVRIO in this trial was generally consistent with that observed in previously reported clinical studies
A total of 889 M&A deals were announced in the medical devices sector in 2022 worth $93 billion
IAGES to focus on upskilling and adoption of advanced Minimal Access Surgery technologies in 2023
Themis will market this drug with the brand name REMITHEM.
According to GlobalData’s analyst consensus forecast, OTX-2002 is projected to have the highest revenue by 2028, with sales of $1.6 billion during that year
Company's Unit - IX, an API intermediate facility situated at Sangareddy District, Telangana, has now been classified as Voluntary Action Indicated
Dr. Dietmar Berger, has agreed to take the leadership of the team ad interim
Subscribe To Our Newsletter & Stay Updated
